Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06343792 · ClinicalTrials.gov registry record · Phase 2
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
A Phase 2 study of Steroid Refractory GVHD, sponsored by ReAlta Life Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 11
- Study locations
NCT06343792: Recruiting Phase 2 study of Steroid Refractory GVHD, sponsored by ReAlta Life Sciences.
NCT06343792 is a Phase 2 study of Steroid Refractory GVHD that is actively recruiting participants, run by ReAlta Life Sciences. The registered enrollment target is 66 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower). The trial reports 11 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06343792, a Phase 2 study of Steroid Refractory GVHD, is actively recruiting participants, sponsored by ReAlta Life Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the secondary treatment of acute Graft-versus-Host Disease (aGvHD) in hospitalized patients who are steroid-refractory.
Conditions Studied
Interventions
- DRUG RLS-0071
Study Locations (11)
Other
- Site 3242 - Freiburg im Breisgau
- Site 3360 - Madrid
- Site 3227 - Salamanca
- Site 3101 - Seville
California
- Site 1091 - Duarte
- Site 1343 - Los Angeles
Ohio
- Site 1100 - Cincinnati
- Site 1382 - Columbus
Georgia
- Site 1318 - Atlanta
Missouri
- Site 1068 - St Louis
SE
- Site 3101 - Seville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2024-08-31 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT06343792 shows while recruiting
NCT06343792 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Steroid Refractory GVHD appearing as the primary indexed condition, and to 1 intervention - of which RLS-0071 is the first listed.
NCT06343792 lists 11 locations in 6 states (Other, California, Ohio).
Frequently Asked Questions
What is clinical trial NCT06343792 about?
NCT06343792 is a clinical study titled "Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease". This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the secondary treatment of acute Graft-versus-Host Disease (aGvHD) in hospitalized patients who are steroid-re...
What is the current status of trial NCT06343792?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2024-08-31. Estimated completion is 2026-12.
What conditions does trial NCT06343792 study?
This clinical trial studies the following conditions: Steroid Refractory GVHD.
What interventions are being tested in trial NCT06343792?
The interventions under investigation include: RLS-0071 (DRUG).
Who is sponsoring clinical trial NCT06343792?
This trial is sponsored by ReAlta Life Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06343792 being conducted?
This trial has 11 study locations across California, Georgia, Missouri, Ohio, SE. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06343792's enrollment target sits among peer trials
66 975th of 2000 higher than 1,014 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI